These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 35792947)
1. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis. Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis. Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M Oncology; 2024; 102(3):228-238. PubMed ID: 37708864 [TBL] [Abstract][Full Text] [Related]
3. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma. Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431 [TBL] [Abstract][Full Text] [Related]
4. Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. Sasaki K; Tsuruda Y; Shimonosono M; Noda M; Uchikado Y; Arigami T; Matsushita D; Mori S; Nakajo A; Kurahara H; Ohtsuka T Anticancer Res; 2022 Aug; 42(8):3905-3911. PubMed ID: 35896244 [TBL] [Abstract][Full Text] [Related]
5. Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan. Matsuda S; Kitagawa Y; Takemura R; Okui J; Okamura A; Kawakubo H; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y Ann Surg; 2023 Jul; 278(1):e35-e42. PubMed ID: 35837977 [TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307 [TBL] [Abstract][Full Text] [Related]
7. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Nomura M; Oze I; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Kawai R; Uemura N; Ishihara M; Tanaka T; Tajika M; Niwa Y; Muro K; Muto M Cancer Chemother Pharmacol; 2015 Aug; 76(2):357-63. PubMed ID: 26092324 [TBL] [Abstract][Full Text] [Related]
8. Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study. Umeki Y; Matsuoka H; Fujita M; Goto A; Serizawa A; Nakamura K; Akimoto S; Nakauchi M; Tanaka T; Shibasaki S; Inaba K; Uyama I; Suda K Intern Med; 2023; 62(3):319-325. PubMed ID: 36725064 [TBL] [Abstract][Full Text] [Related]
9. Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer. Sugase T; Sugimura K; Kanemura T; Takeoka T; Yamamoto M; Shinno N; Hara H; Omori T; Fujii Y; Mukai Y; Mikamori M; Hasegawa S; Haraguchi N; Akita H; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H Oncology; 2022; 100(12):655-665. PubMed ID: 36198297 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus. Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus. Yamagata Y; Saito K; Hirano K; Oya M World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma. Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230 [TBL] [Abstract][Full Text] [Related]
13. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial). Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence. Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M Oncology; 2017; 92(4):221-228. PubMed ID: 28110330 [TBL] [Abstract][Full Text] [Related]
15. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y; Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531 [TBL] [Abstract][Full Text] [Related]
17. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815 [TBL] [Abstract][Full Text] [Related]
18. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775 [TBL] [Abstract][Full Text] [Related]
19. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma. Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432 [TBL] [Abstract][Full Text] [Related]
20. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]